Abreva News and Research RSS Feed - Abreva News and Research

GSK, NanoBio initiate two NB-001 Phase 3 trials in cold sores

GSK, NanoBio initiate two NB-001 Phase 3 trials in cold sores

NanoBio Corporation today announced the initiation of two Phase 3 multicenter trials evaluating NB-001 as a topical treatment for cold sores, a step forward in their OTC licensing agreement with GlaxoSmithKline Consumer Healthcare. [More]
BeaconEquity.com announces investment report featuring Avanir Pharmaceuticals

BeaconEquity.com announces investment report featuring Avanir Pharmaceuticals

BeaconEquity.com announces an investment report featuring Avanir Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision. [More]
Over-the-counter medications can help manage minor ailments

Over-the-counter medications can help manage minor ailments

Nonprescription medications in the home medicine cabinet could save a trip to the doctor. The January issue of Mayo Clinic Health Letter lists more than a dozen over-the-counter medications that can help manage minor ailments. [More]
GSK and NanoBio sign license agreement for nanoemulsion technology

GSK and NanoBio sign license agreement for nanoemulsion technology

GlaxoSmithKline and Ann Arbor-based NanoBio Corporation announced today that they have signed an exclusive over-the-counter licensing agreement for NanoBio's unique nanoemulsion treatment for cold sores in the United States and Canada. [More]
NanoBio, GSK partner to develop and commercialize novel cold sore treatment compound

NanoBio, GSK partner to develop and commercialize novel cold sore treatment compound

GlaxoSmithKline plc and NanoBio Corporation today announced an exclusive licensing agreement in the United States and Canada for the over-the-counter (OTC) use of NB-001, a novel, patented compound representing the next advance in the treatment of cold sores. Developed by NanoBio, NB-001 provides significant antimicrobial activity against the virus that causes cold sores, herpes labialis. [More]
Advertisement
Advertisement